RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis

Across the two pivotal trials, RINVOQ delivered rapid and meaningful disease control with nearly half of ankylosing spondylitis (AS) patients achi...

Related Keywords

United States ,Ohio ,Oregon ,America ,American ,Thomas Hudson ,Cassie Shafer ,Instagram ,Linkedin ,Twitter ,Drug Administration ,Rheumatic Diseases At Oregon Health Science University ,Exchange Commission ,Allergan ,Facebook ,Abbvie Inc ,Spondylitis Association Of America ,Rheumatology Clinics For The Division Of Arthritis ,Atul Deodhar ,Rheumatology Clinics ,Rheumatic Diseases ,Oregon Health ,Science University ,Spondylitis Association ,Bath Ankylosing Spondylitis Functional Index ,Patient Global Assessment ,Disease Activity ,Total Back Pain ,Abbvie Assist ,Important Safety ,Mississippi River ,Full Prescribing Information ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,North Chicago ,Evaluate Efficacy ,Adult Participants With Axial Spondyloarthritis ,Maintenance Therapy ,Subjects With Moderately ,Severely Active Ulcerative ,Placebo Controlled Study ,Endoscopic Remission ,Severely Active Crohn ,Disease Who Have Inadequately Responded ,Are Intolerant ,Participants With Giant Cell Arteritis ,Study Comparing Upadacitinib ,Participants With Psoriatic Arthritis Who Have ,Inadequate Response ,Compare Safety ,Adult Participants With Moderate ,Severe Atopic Dermatitis ,Subjects With Takayasu Arteritis ,